Early peritoneal mesothelioma: a treatable malignancy

Area of Science:

• Oncology
• Medical Imaging

Background:

• Malignant peritoneal mesothelioma is a rare and aggressive cancer.
• Combined therapeutic approaches are being investigated for improved patient outcomes.

Purpose of the Study:

• To evaluate the efficacy of combined therapy in patients with malignant peritoneal mesothelioma.
• To compare survival rates between intensive and palliative treatment strategies.
• To identify prognostic factors, such as age, influencing survival.

Main Methods:

• Retrospective analysis of 37 patients diagnosed with malignant peritoneal mesothelioma.
• Categorization of patients into intensive and palliative treatment groups.
• Utilized computed tomographic (CT) scans for disease assessment.
• Compared survival data between treatment groups and age cohorts.

Main Results:

• Intensively treated patients (n=6) showed 100% survival with no evidence of disease at 9-36 months post-treatment.
• Palliatively treated patients (n=8) had a lower survival rate, with 5 deaths.
• Survival in the intensively treated group was significantly better than other stage I patients.
• Patients under 40 years of age demonstrated a significantly better survival rate.

Conclusions:

• Combined therapy, particularly when administered intensively, offers superior survival outcomes for malignant peritoneal mesothelioma.
• Age is a significant prognostic factor, with younger patients (<40) experiencing better survival.
• Further research into optimized combined therapeutic strategies is warranted.